Lemtrada shows clinical efficacy in multiple sclerosis in 10-year follow-up data

pharmafile | April 20, 2016 | News story | Research and Development, Sales and Marketing Lemtrada, Sanofi, alemtuzumab, multiple sclerosis, sanofi genzyme 

Sanofi Genzyme has presented 10-year follow-up data on Lemtrada (alemtuzumab) which points to its efficacy in patients with relapsing-remitting multiple sclerosis (RRMS).

The ongoing Phase II CAMMS223 study showed that, over 10 years of follow-up, 76% of patients were shown to be free from 6-month confirmed disability worsening. Furthermore, a low annualised relapse rate (ARR) was maintained (0.08) over the period, while long term safety was observed in the trial patients that were consistent with other trials for Lemtrada.

Professor Alasdair Coles, lead investigator of the study from the University of Cambridge school of clinical medicine, says: “These data provide further evidence of the long term response with Lemtrada in treatment-naïve patients with relapsing-remitting MS. It is remarkable that such infrequent dosing with Lemtrada offers stability or improvement of disability over ten years. These findings confirm that Lemtrada is a valid treatment approach for people with multiple sclerosis, without the need for continuous treatment.”

More than 100,000 people in the UK have MS, with around 85% of those diagnosed with relapsing remitting multiple sclerosis. Lemtrada is the second of Sanofi Genzyme’s treatments for MS to have received approval from NICE for use in the NHS in England and Wales.

Peter Kuiper, General Manager UK & Ireland at Sanofi Genzyme, comments: “We are very pleased with these new data, which are part of our extensive clinical development programme and our commitment to the field of MS. Being able to offer this treatment option, which was discovered and developed in the UK to clinicians and their patients, is of incredible importance to us.”

The data was presented at the American Academy of Neurology 2016 Annual Meeting in Vancouver.

Sean Murray

Related Content

Sanofi and Regeneron share results from phase 3 trial for Dupixent as COPD treatment

Sanofi and Regeneron have announced results from the second investigational phase 3 NOTUS trial for …

Sanofi shares new data for long-term efficacy of Nexviazyme for Pompe disease treatment

Sanofi has shared new data for the long-term efficacy of Nexviazyme (avalglucosidease alfa) for the …

Janssen and Sanofi enter agreement for potential vaccine programme

Janssen Pharmaceuticals, a Johnson & Johnson company, has announced a development and commercialisation agreement with …

Latest content